Peptide Tools to Study Influenza Virus

About the Influenza Virus
Influenza viruses belong to the orthomyxoviridae family. These are enveloped viruses with a segmented, negative-sense, single- stranded RNA genome. Only orthomyxoviridae Influenza type A and B cause disease in humans. Their main antigenic determinants are the two transmembrane proteins hemagglutinin (‘H’ or ‘HA’) and neuraminidase (‘N’ or ‘NA’).
The combinations of specific variants of the H (H1-H18) and N (N1-N11) proteins are used to classify Influenza A viruses into subtypes. The standard WHO nomenclature for a given human influenza virus comprises the genus (‘A’), the geographical site where they were first identified (e.g. Hong Kong), a serial number and the identification year (e.g. 1/1968), and finally the H and N variants.

JPT offers a range of highly relevant Influenza virus-specific antigen peptides, PepMix™ peptide pools and PepStar™ peptide microarrays.

JPT's Peptide Tools to Study Influenza

Cellular Immune Response

--> PepMix™ Peptide Pool applications include
  • Antigen specific stimulation of T-cells
  • Immune monitoring of high-risk patients
  • Identification of immunodominant antigens
  • Validating clinical T-cell assays

The following Influenza A PepMix™ Peptide Pools are available
  • H1N1 (Brisbane): HA
  • H1N1 (California): HA, Membrane protein 1 &2, NA
  • H1N1 (Puerto Rico): HA
  • H2N2 (AnnArbor): Membrane protein 1 &2, Nucleocapsid protein
  • H3N2 (HongKong) : HA, MP1, Nucleocapsid protein
  • H5N1 (Indonesia): HA
  • H5N1 (Turkey): NA
  • H10N8 (Jiangxi): HA

Among others, our positive 
control pools also contain Influenza A antigens (CEF, CEFT, EF).

JPT also offers custom-designed PepMix™ Peptide Pools for your specific needs!

Humoral Immune Response

PepStar™ Peptide Microarray applications include
  • Immune monitoring of humoral responses
  • Profiling of Influenza-specific samples or antibodies
  • Detection of epitopes and epitope spreading

The following Influenza A PepStar™ Peptide Microarrays are available
  • H1N1 (Brisbane): HA
  • H1N1 (California): HA, NA, membrane protein 1 &2,
  • H3N2: Membrane protein 1, nucleocapsid protein
  • Antigen Collection Influenza A Ultra

You define content and layout, we provide economic and fast production in our regulated clean-room environment.
Ship your samples and obtain high-quality results analysed by experts! We also offer a complete assay and analysis service for your samples using your own, custom-designed peptide microarray.

Clinical Peptides

JPT’s clinical peptide product lines, ‘Clinical Grade’ and ‘ISO Plus’, are produced in a tightly regulated production environment according to an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy, vaccine, and drug development. Our products have been approved for clinical use with respect to specific immunotherapeutic applications. Please consult our website.


2021 - 2022

2021 - 2022

  • Transcriptional Programs of Neoantigen-Specific TIL in Anti-PD-1-Treated Lung Cancers
    Caushi et al., Nature (2021) - PMID: 34290408
  • M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain
    Eiden et al., Journal of Infectious Diseases (2021) - PMID: 34323977
  • A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
    Koonpaew et al., Vaccines (2021) - PMID: 34451975
  • Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
    Van den Berg, Journal of Immunology (2022) - PMID: 34025665
  • Polyfunctional pathogen-specific CD4+ T cells reside in the lungs and tumors of NSCLC patients
    Oja et al., BioRxiv (2022)
  • A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2
    Ilinykh et al., Vaccines (2022) - PMID: 35468973
Application Notes

Application Notes


Check our list of products, click and go.

Get a quote